Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
128 results about "Adenylyl cyclase activation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cyclic AMP is an important molecule in eukaryotic signal transduction, a so-called second messenger. Adenylyl cyclases are often activated or inhibited by G proteins, which are coupled to membrane receptors and thus can respond to hormonal or other stimuli.
Enzymatic fluorimetric assay of camp and adenylate cyclase
InactiveUS6762026B1Easy to operateReaction period can be extremely shortenedMicrobiological testing/measurementMaterial analysisRadioactive agentFluorescence
The present invention relates to a method for quickly determining cAMP content or an adenylate cyclase activity in a biological sample containing non-cyclic adenine nucleotides without the use of radioactive agents.Particularly, the present invention provides a method of determining cAMP content or an adenylate cyclase activity in a biological sample containing non-cyclic adenine nucleotides selected from the group consisting of cAMP produced by endogenous adenylate cyclase, and AMP, ATP, ADP and a mixture thereof, which comprises (1) combining a biological sample with effective amounts of apyrase, adenosine deaminase and alkaline phosphatase to enzymatically remove non-cyclic adenine nucleotides other than cAMP, and glucose-6-phosphate in the sample; (2) enzymatically converting cAMP into AMP; (3) determining an amount of AMP without the use of radioactive agents, and a kit to carry out the method.
Owner:FUSO PHARMA INDS
Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
InactiveUS20070149439A1Facilitated DiffusionNervous disorderPeptide/protein ingredientsDiseaseIn vivo
Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor system can be manipulated positively or negatively to regulate mitosis in neuronal precursor cells. The ligand / receptor system involves PACAP, PACAP receptor, PAC1, and related antagonists. The methods of regulation of the present invention may model be used to define cell cycle regulation in the developing neurons. The present invention may also be used to control or cure diseases related to or caused by damage to or destruction of neuronal cells.
Owner:DICICCO BLOOM EMANUEL +3
Compositions and methods for treating ileus
InactiveUS20050075290A1Preventing ileusEffective amountPeptide/protein ingredientsPeptide preparation methodsCyclasePituitary adenylate cyclase-activating peptide
The present invention is directed to compositions useful in treating or preventing ileus in a patient. The compositions of the invention include a pituitary adenylate cyclase activating peptide (PACAP) receptor antagonist and / or a vasoactive intestinal peptide (VIP) receptor antagonist in an amount sufficient to treat or prevent ileus in a patient. In one embodiment both a PACAP and VIP receptor antagonists are present, preferably in a combination that blocks vasoactive pituitary cyclase 1 (VPAC1), VPAC2 and pituitary adenylate cyclase 1 (PAC1) receptors. Methods of using such composition to treat or prevent ileus in a patient are also encompassed by the invention.
Owner:VIPOGEN
Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
InactiveUS20080221041A1High activityPromote circulationPeptide/protein ingredientsMetabolism disorderDiseaseWhole body
The present invention relates to peptides which are highly biologically and pharmacologically active as therapeutic drug for the treatment of diseases related to hypertension, especially in medical interventions involving dilatation and remodeling of arterial blood vessels, either in the pulmonary or in the systemic circulation. The peptides which can be used according to the invention for the treatment of said diseases comprise at least one specific highly conservative amino acid residue sequence which seem to play an important role in connection with pulmonary and arteriolar hypertension events. It could be shown that the known naturally occurring peptides “vasoactive intestinal peptide (VIP)” and “pituitary adenylate cyclase-activating polypeptide (PACAP)”, having these specific sequences are potent drugs which can be successfully used for treatment of primary pulmonary hypertension (PPH), secondary pulmonary hypertension (SPH), and hypertension of the systemic circulation. Furthermore, the present invention discloses pharmaceutical compositions useful for treatment of PPH, SPH, and hypertension of the systemic circulation within said methods.
Owner:MONDOBIOTECH AG
Method of Enhancing Neural Stem Cell Proliferation, Differentiation, and Survival Using Pituitary Adenylate Cyclase Activating Polypeptide (PACAP)
InactiveUS20070179092A1Enhancing neural stem cell proliferationConducive to survivalNervous disorderPeptide/protein ingredientsDiseaseFactor ii
The present invention relates to a method of increasing the number and / or differentiation of neural stem cells and / or neural stem cell progeny using pituitary adenylate cyclase-activating polypeptide (PACAP). In a preferred embodiment, additional growth factors are also utilized. The present invention can be practiced in vivo and in vitro, rendering it useful for the treatment of neurodegenerative disease and other neural trauma.
Owner:STEM CELL THERAPEUTICS
Method for treating lung diseases associated with ventilation-perfusion mismatches
InactiveUS20050118109A1Improving and recovering general state of healthAntibacterial agentsBiocideVasoactive intestinal peptideObstructive Pulmonary Diseases
The present invention relates to pharmaceutical compositions and methods for the prevention and / or treatment of lung diseases or disorders including the bronchial tree, in an animal or human, such as chronic obstructive pulmonary disease (COPD), and diseases related to or optionally associated with COPD-like lung disorders caused by ventilation-perfusion mismatches preferably in context with chronic bronchitis. The treatment includes administration of pharmaceutical compositions comprising vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), and biologically active analogues thereof, which comprise highly conservative sequence tracks.
Owner:BLOCK LUTZ HENNING +2
ADP detection based methods using adenylate cyclase and bioluminescence
ActiveUS8183007B2Easy to measureFast, sensitive, simple, and non-radioactivePeptide/protein ingredientsMicrobiological testing/measurementLipid formationATP Hydrolase
The disclosure provides compositions and methods to determine or detect ADP or the activity of enzymes, including phosphotransferases such as kinases (e.g., protein, lipid, and sugar kinases) and ATP hydrolases such as ATPases, e.g., HSP90, that employ ATP as a substrate and form ADP as a product by monitoring changes in ADP.
Owner:PROMEGA CORP
Parathyroid hormone analogues and methods of use
InactiveUS20070270341A1High densityRestore bonePeptide/protein ingredientsSkeletal disorderSide effectParathyroid Hormone Analogue
The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects.
Owner:MORLEY PAUL +2
Method for treating the endotoxic shock in mammals
InactiveUS6429188B1Inhibit productionImprovement in evolutionBiocidePeptide/protein ingredientsToxinInterleukin 6
Method for the treatment of endotoxic shock in mammals. The use of vasoactive intestinal peptide (VIP) and peptide activating hypofissiary adenylate cyclase (PACAP) is described in the treatment of endotoxic shock in mammals. These substances inhibit the production of tumor necrosis factor (TNF) and interleukin 6 (IL-6).
Owner:UNIV COMPLUTENSE DE MADRID
Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (PACAP)
InactiveUS7368115B2Enhance proliferation and survival and differentiationIncrease differentiationNervous disorderPeptide/protein ingredientsDiseaseIn vivo
Owner:STEM CELL THERAPEUTICS
Parathyroid hormone analogues and methods of use
InactiveUS20070099831A1Increasing bone mineral densityRestore boneBiocideOrganic active ingredientsPhospholipaseParathyroid Hormone Analogue
The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose of 2 μg to 60 μg, wherein said PTH peptide analogue has a reduced phospholipase-C activity and maintains adenylate cyclase activity.
Owner:ZELOS THERAPEUTICS
Compositions and methods for treating ileus
The present invention is directed to compositions useful in treating or preventing ileus in a patient. The compositions of the invention include a pituitary adenylate cyclase activating peptide (PACAP) receptor antagonist and / or a vasoactive intestinal peptide (VIP) receptor antagonist in an amount sufficient to treat or prevent ileus in a patient. In one embodiment both a PACAP and VIP receptor antagonists are present, preferably in a combination that blocks vasoactive pituitary cyclase 1 (VPAC1), VPAC2 and pituitary adenylate cyclase 1 (PAC1) receptors. Methods of using such composition to treat or prevent ileus in a patient are also encompassed by the invention.
Owner:VIPOGEN
Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
InactiveUS20080274961A1High activityMetabolism disorderTripeptide ingredientsDiseaseVasoactive intestinal peptide
Owner:THERAMETRICS DISCOVERY AG
Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
InactiveUS20130065816A1Good curative effectPrevent proliferationAntibacterial agentsSenses disorderMedical disorderAutoimmune condition
This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP / vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic / therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic / therapeutic agents.
Owner:TULANE EDUCATIONAL FUND
Adenosine A3 receptor agonist
InactiveUS20030143282A1Sugar derivativesPeptide/protein ingredientsLiquid mediumAdenosine A3 Receptor Agonists
The present invention relates to a naturally occurring low molecular weight adenosine A3 receptor agonist (LMW-A3RAg) which is preferably obtained from a vertebrate tissue or a vertebrate-derived cell by extraction in a liquid medium. The LMW-A3RAg of the invention is characterized by the following feature: (i) it is obtainable from animal-derived tissue or cells; (ii) it filters through a filter with a maximal molecular weight cut-off of about 3,000 Daltons; (iii) it is water soluble, heat stable, non-proteinaceous and resistant to adenosine deaminase activity. The invention also concerns pharmaceutical compositions comprising the naturally occurring LMW-A3RAg of the invention and therapeutic methods comprising administering to a subject in need an effective amount of the naturally occurring A3RAg for achieving a therapeutic effect, the therapeutic effect comprises inhibition of adenylate cyclase in target cells.
Owner:CAN-FITE BIOPHARMA LTD
Recombination fusion protein PACAP-PTD (Pituitary Adenylate Cyclase Activating Peptide-Protein Transduction Domain) as well as expression method and application thereof
InactiveCN102079790ABiologically activeCapable of transporting across biological barriersSenses disorderNervous disorderDiseaseNucleotide
The invention discloses a recombination fusion protein PACAP-PTD (Pituitary Adenylate Cyclase Activating Peptide-Protein Transduction Domain) as well as an expression method and application thereof. The amino acid sequence of the recombination fusion protein PACAP-PTD provided by the invention is shown as SEQ ID NO: 1 and the nucleotide sequence encoding the protein is shown as SEQ ID NO: 2. The recombination fusion protein PACAP-PTD provided by the invention has biological activity of PACAP and gives a function of transcellular barrier transport of the PTD to the PACAP to ensure that the function of cellular barrier traversing transport can be provided, therefore, blood brain barrier, cornea, qi-blood barrier, testis barrier, endothelium and mucosa organization and the like can be effectively traversed; the application value of the PACAP-PTD in diseases related to parts of brain, eyes, lung, genitals and the like can be greatly enhanced; the route of administration can be improved; and the application range can be extended.
Owner:JINAN UNIVERSITY
Recombinant adenylate cyclase of Bordetella sp. for diagnostic and immunomonitoring uses, method of diagnosing or immunomonitoring using said recombinant adenylate cyclase, and kit for diagnosing or immunomonitoring comprising said recombinant adenylate cyclase
InactiveUS20060019323A1Enhanced T cell responseImprove responseMicrobiological testing/measurementBiological material analysisAntigenCyaA
Diagnostic testing and immunomonitoring that uses genetically detoxified Bordetella pertussis CyaA as a delivery system are effective in tracking any immune responses, such as those generated by infectious and non-infectious diseases, or vaccinations, for example. T cells previously stimulated by a given antigen can be restimulated in vitro by the same antigen fused or chemically coupled to CyaA or a fragment thereof. The invention includes diagnostic tests and immunomonitoring for tuberculosis by providing a delivery system, which can deliver the M. tuberculosis immunodominant proteins ESAT-6 and CFP-10, to human cells and non-human animal cells, such as cattle. In addition, fusion proteins between CyaA and cancer antigens are also provided as diagnostic tests and immunomonitoring systems for cancers, such as melanoma.
Owner:INST PASTEUR
Recombinant Escherichia coli capable of highly producing cyclic adenosine monophosphate and application of recombinant Escherichia coli
ActiveCN102433292AHigh catalytic activityImprove catalytic stabilityBacteriaMicroorganism based processesEscherichia coliRecombinant escherichia coli
The invention discloses recombinant Escherichia coli capable of highly producing cyclic adenosine monophosphate. The systematic nomenclature is Escherichia coli; and the collection number is CGMCC No.4706. The invention also discloses application of the recombinant Escherichia coli capable of highly producing the cyclic adenosine monophosphate to the production of the cyclic adenosine monophosphate. In the invention, an adenylate cyclase gene which is obtained by cloning a cAMP producing strain shows high catalytic activity and stability in the whole-cell catalysis process of recombinant bacteria, and ensures that the conversion rate of a substrate, namely adenosine triphosphate (ATP) reaches over 90 percent; and the reaction system is simple, conditions are mild, the period is short, few byproducts are generated, and the method is clean and pollution-free and is a simple, quick and efficient production way.
Owner:NANJING UNIV OF TECH
USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) COMPLEXES
InactiveUS20120309683A1Protecting the major organsEffective protectionNervous disorderMetabolism disorderUveitisAutoimmune responses
This invention relates to methods and compositions for the treatment, management, reduction, or prevention of injuries to one or more major organs of the body, e.g., the brain, heart, lung, kidneys, liver, and gastrointestinal tract, of a mammal (e.g., a human) caused by one or more calcineurin or mammalian target of rapamycin (mTOR) complex inhibitors. The methods include administering an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds to the mammal. Combination therapy with one or more PACAP-like compounds, either alone or in combination with one or more other prophylactic / therapeutic agents, plus one or more inhibitors of either calcineurin or the mTOR complexes can be used to treat organ transplantation, autoimmune diseases, graft-versus-host disease, Behçet's disease, hematological cancers, noninfectious uveitis, sarcoidosis, tuberous sclerosis complex, acute neurological diseases, age-related neurodegenerative diseases, Huntington's disease and other CAG codon repeat expansion diseases, keratoconjunctivitis sicca, and restenosis.
Owner:THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
Method for inducing neural differentiation
InactiveUS20050287665A1Safe and effective in changeFix bugsOrganic active ingredientsNervous disorderGlial cell line-derived neurotrophic factorBone Marrow Stem Cell
The present invention provides a method for inducing neural differentiation comprising treating a bone marrow stem cell with a neurotrophic factor and / or dibutyryl cAMP (dbcAMP), wherein the neurotrophic factor comprises glial cell line-derived neurotrophic factor (GDNF) or pituitary adenylate cyclase-activating polypeptide (PACAP).
Owner:HENRICH CHENG
Compositions and methods for enhancing weight-loss by cyclical administration of compounds
InactiveUS7977378B1Promotes energyPromotes satietyBiocideOrganic compound preparationBlister packBuccal administration
Compositions and methods are provided for the treatment of obesity in a human in need of such treatment which comprises administration to the human of a therapeutically effective amount of a compound of a weight loss enhancing beta-3-adrenergic compound of Cycle I, and a different weight loss enhancing adenylate cyclase receptor replenishing compound of Cycle II, in conjunction with a pharmaceutically acceptable diluent or carrier, wherein the Compound of Cycle I and the compound of Cycle II are administered sequentially. The composition may be present as a kit having each sequence in blister packs.
Owner:VILLALOBOS ADEL
Leptin-mediated gene-induction
InactiveUS7291458B2Inducing effectObesity gene productsPeptide/protein ingredientsProtein iThreonine
Methods of activating a signaling cascade comprising, introducing leptin and / or a cytokine to a receptor complex comprising gp 130, optionally in combination with a compound acting on adenylate cyclase or acting on one or more downstream targets of adenylate cyclase, thereby inducing genes in neuro-endocrine cells or cells of neuro-endocrine origin. Two distinct gene-sets are induced, immediate early response genes (STAT-3, SOCS-3, Metallothionein-II, the serine / threonine kinase Fnk and the rat homologue of MRF-1), and late induced target genes (Pancreatitis Associated Protein I, Squalene Epoxidase, Uridinediphosphate Glucuronyl Transferase and Annexin VIII). Strong co-stimulation with the adenylate cyclase activator forskolin was shown with respect to late induced target genes. Transcripts encoding Leptin Induced Protein I (LIP-I) and Leptin Induced Protein II (LIP-II) were identified; however, no forskolin co-stimulatory effect was observed. It is also demonstrated that leptin modulates in vivo expression of MT-II, Fnk and Pancreatitis Associated Protein I genes.
Owner:NEC CORP +1
Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
InactiveUS20160122406A1Reduce harmPrevent restenosisCompounds screening/testingNervous disorderMedical disorderDisseminated cancer
This invention relates to analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP / vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic / therapeutic agents for a wide range of medical disorders. These PACAP analogs coupled to suitable radionuclides can be used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, and coupled to small molecule therapeutics can be used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP analogs of the invention either alone or in combination with one or more other prophylactic / therapeutic agent.
Owner:TULANE EDUCATIONAL FUND
Pacap antibodies and uses thereof
ActiveUS20180362643A1Avoid adjustmentNervous disorderPharmaceutical delivery mechanismHeadachesCluster headache
The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
Owner:AMGEN INC
Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
InactiveUS8916517B2Prevent proliferationEfficaciousAntibacterial agentsSenses disorderMedical disorderDisease
Owner:THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
Parathyroid hormone analogues and methods of use
InactiveUS20080176787A1Increasing bone mineral densityRestore bonePeptide/protein ingredientsSkeletal disorderSide effectParathyroid Hormone Analogue
The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects.
Owner:ZELOS THERAPEUTICS
Compositions and methods for identifying modulators of transducisomes, a new class of therapeutic targets
InactiveUS20070150970A1Avoid signalingHigh selectivityAnimal cellsCell receptors/surface-antigens/surface-determinantsPhospholipaseElectrical conductor
Owner:LIFE TECH CORP
Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens
ActiveUS20100063099A1Prevent diseaseSuppress gene expressionBiocideHydroxy compound active ingredientsDiseaseScreening method
The present invention relates to a method of preventing or treating a disease caused by infection by a eukaryotic pathogen, wherein the method comprises administering an effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of a eukaryotic pathogen's adenylyl cyclase that do not substantially modulate an adenylyl cyclase of the subject. The invention also provides methods for culturing eukaryotic pathogens and methods for inducing the pathogenic state in vitro.
Owner:CORNELL RES FOUNDATION INC
Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and pacap analogs as adjunctive treatments with anticancer agents
InactiveUS20110268789A1Protecting the major organs of the bodyEffective protectionBiocidePowder deliveryVIP ReceptorsAnticarcinogen
This invention relates to methods and compositions for the treatment, management or prevention of injuries to one or more of the organs of the body, such as the brain, heart, lung, kidneys, liver, and gastrointestinal tract, of humans or other mammals caused by one or more anticancer agents. The methods of this invention consist of the administration of an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds, which includes native human PACAP38, native human PACAP27, native human vasoactive intestinal peptide (VIP), their agonists, analogs, fragments, and derivatives, with activities toward one or more of the PACAP / VIP receptors, including all of their various isoforms. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic / therapeutic agents useful for the treatment, management or prevention of injuries to the organs of the body of humans or other mammals undergoing cancer chemotherapy. Combination therapy with one or more PACAP-like compounds plus one or more anticancer agents can be used in the treatment of hematological cancers.
Owner:TULANE EDUCATIONAL FUND
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com